Analysts Expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to Post -$0.37 EPS

Wall Street analysts forecast that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRXGet Rating) will post ($0.36) earnings per share for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for BioCryst Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.51) and the highest estimate coming in at ($0.20). BioCryst Pharmaceuticals posted earnings of ($0.24) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 50%. The business is scheduled to announce its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that BioCryst Pharmaceuticals will report full-year earnings of ($1.37) per share for the current financial year, with EPS estimates ranging from ($1.94) to ($1.00). For the next fiscal year, analysts forecast that the business will report earnings of ($0.66) per share, with EPS estimates ranging from ($1.38) to $0.75. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals (NASDAQ:BCRXGet Rating) last released its quarterly earnings data on Wednesday, February 23rd. The biotechnology company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.09). The company had revenue of $47.16 million during the quarter, compared to analyst estimates of $48.18 million.

BCRX has been the subject of a number of recent analyst reports. Bank of America downgraded BioCryst Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $21.00 to $14.00 in a report on Monday, April 11th. Oppenheimer lowered their price target on BioCryst Pharmaceuticals from $16.00 to $13.00 and set an “outperform” rating for the company in a report on Friday. StockNews.com downgraded BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday. Royal Bank of Canada lowered their price target on BioCryst Pharmaceuticals from $16.00 to $14.00 and set a “sector perform” rating for the company in a report on Tuesday, April 12th. Finally, Barclays downgraded BioCryst Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $22.00 to $13.00 in a report on Monday, April 18th. One analyst has rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $17.67.

NASDAQ BCRX opened at $8.39 on Friday. The stock has a 50-day simple moving average of $13.22 and a 200 day simple moving average of $13.92. The company has a market capitalization of $1.56 billion, a PE ratio of -7.84 and a beta of 2.51. BioCryst Pharmaceuticals has a 12 month low of $7.61 and a 12 month high of $19.99.

In related news, Director George B. Abercrombie sold 5,000 shares of the stock in a transaction that occurred on Tuesday, February 15th. The stock was sold at an average price of $18.50, for a total transaction of $92,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Helen M. Thackray sold 7,600 shares of the stock in a transaction that occurred on Friday, April 1st. The shares were sold at an average price of $16.20, for a total value of $123,120.00. Following the transaction, the insider now directly owns 136,400 shares of the company’s stock, valued at $2,209,680. The disclosure for this sale can be found here. 4.80% of the stock is owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in BCRX. J.W. Cole Advisors Inc. increased its stake in shares of BioCryst Pharmaceuticals by 2.0% during the fourth quarter. J.W. Cole Advisors Inc. now owns 36,800 shares of the biotechnology company’s stock worth $510,000 after purchasing an additional 735 shares during the period. Semmax Financial Advisors Inc. increased its stake in shares of BioCryst Pharmaceuticals by 389.6% during the first quarter. Semmax Financial Advisors Inc. now owns 1,699 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,352 shares during the period. Kalos Management Inc. increased its stake in shares of BioCryst Pharmaceuticals by 7.0% during the fourth quarter. Kalos Management Inc. now owns 25,359 shares of the biotechnology company’s stock worth $340,000 after purchasing an additional 1,659 shares during the period. E Fund Management Co. Ltd. increased its stake in shares of BioCryst Pharmaceuticals by 11.8% during the first quarter. E Fund Management Co. Ltd. now owns 16,641 shares of the biotechnology company’s stock worth $271,000 after purchasing an additional 1,756 shares during the period. Finally, DekaBank Deutsche Girozentrale increased its stake in shares of BioCryst Pharmaceuticals by 2.8% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 67,065 shares of the biotechnology company’s stock worth $894,000 after purchasing an additional 1,800 shares during the period. Hedge funds and other institutional investors own 63.86% of the company’s stock.

About BioCryst Pharmaceuticals (Get Rating)

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

Further Reading

Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.